Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Goals Needed To Balance FDA Caution, Former Counsel Troy Says

Executive Summary

The prescription drug user fee program must be preserved to prevent FDA from becoming overly cautious on drug approvals, former FDA Chief Counsel Dan Troy told the Milken Institute Global Conference in Los Angeles April 18

You may also be interested in...



Drug Safety Debate Will Have Long-Term Effect On New Approvals, Troy Says

The current debate over drug safety will have a visible impact on new drug approvals in up to three years, former FDA Chief Counsel Dan Troy said

Drug Safety Debate Will Have Long-Term Effect On New Approvals, Troy Says

The current debate over drug safety will have a visible impact on new drug approvals in up to three years, former FDA Chief Counsel Dan Troy said

FDA’s Crawford Open To Discussing Independent Drug Safety Office

FDA Acting Commissioner Lester Crawford is willing to consider making the Office of Drug Safety formally independent from drug review activities if he is confirmed as the agency's permanent leader

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel